02171.HK
CARsgen Therapeutics Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 10.95
−2.67%Year over year
Reported trailing growth
- Revenue
- +62.6%
- EBITDA
- +41.1%
- EBIT
- +81.1%
- EPS
- +83.8%
- Free cash flow
- +47.8%
- Operating cash flow
- +51.5%
Forward estimates
Based on analyst estimates
- Revenue
- +58.0%
- EBITDA
- +65.7%
- EPS
- +4.8%
Three-year CAGR
- Revenue
- +218.7%
- EBITDA
- +58.9%
- EBIT
- +87.1%
- Net income
- +87.7%
- EPS
- +87.5%
- Free cash flow
- +43.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026